Redeye retains its positive view of Addnode following a solid Q4 report.
* Continued soft demand and hourly prices * '26e-'27e EBITA down 3% * Trading at ~5x NTM EV/EBITA, ~...
We lower sales by 4% and cut EBIT by SEK 4-12m in 2026E-28E.
* Mixed Q4 but continued operational leverage * Estimates down on adj.
Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-tar...
CapMan makes another exit from its Buyout funds as the company just announced exit of PDSVISION from...
Vaisala reports Q4 results on Feb 12. We believe Vaisala’s FY’25 EBITA improved only slightly y/y, w...
Consti reports Q4 results on February 6th, which we expected to be quite in line with previous year ...
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj.
Redeye comments on Addnode’s Q4 report, showing a solid EBITA beating our expectations by 4%.
Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and...
Redeye initiates coverage of ExpreS2ion Biotech, a clinical-stage Scandinavian biotech company devel...
* Strong Q4 on the cards: EBIT SEK 41m (SEK -18m Q4'24) * Slightly lowered Q4 assumptions, but '26e-...
* Q4 NAV in line with ABGSCe * Strong operational performance in key private assets * P/NAV lower, d...
Finnair reports Q4 results on Feb 11. FY’25 was challenging due to labor issues, but right now the o...
Grangex löser fler och fler frågor inför starten av Sydvarangergruvan, vilket sänker risken i väntan...
* Underlying performance indicative of a brighter '26e * '26e-'27e adj.
Redeye updates on Embracer ahead of Q3-results (due 12 February) where we expect another quarter wit...
Redeye updates its estimates and valuation after Indutrade’s Q4 2025 report.
Besqab posted a record-strong Q4 with a high number of starts and strong earnings growth, with EBIT ...
